Syndax Pharmaceuticals Inc Financials

SNDX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Syndax Pharmaceuticals Inc (SNDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Syndax Pharmaceuticals Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Syndax Pharmaceuticals Inc generates $0.86 in operating cash flow (-$274.9M OCF vs -$318.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-68.9x

Syndax Pharmaceuticals Inc earns $-68.9 in operating income for every $1 of interest expense (-$339.7M vs $4.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$23.7M

5Y CAGR+73.3%

Syndax Pharmaceuticals Inc generated $23.7M in revenue in fiscal year 2024.

EBITDA

-$331.7M

YoY-52.2%

Syndax Pharmaceuticals Inc's EBITDA was -$331.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.2% from the prior year.

Free Cash Flow

N/A

Net Income

-$318.8M

YoY-52.3%

Syndax Pharmaceuticals Inc reported -$318.8M in net income in fiscal year 2024. This represents a decrease of 52.3% from the prior year.

EPS (Diluted)

$-3.72

YoY-24.8%

Syndax Pharmaceuticals Inc earned $-3.72 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 24.8% from the prior year.

Cash & Debt

$154.1M

YoY-47.8%

5Y CAGR+44.3%

10Y CAGR+31.4%

Syndax Pharmaceuticals Inc held $154.1M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

86M

YoY+1.0%

5Y CAGR+25.9%

Syndax Pharmaceuticals Inc had 86M shares outstanding in fiscal year 2024. This represents an increase of 1.0% from the prior year.

Gross Margin

N/A

Operating Margin

-1434.4%

5Y CAGR+2358.5pp

Syndax Pharmaceuticals Inc's operating margin was -1434.4% in fiscal year 2024, reflecting core business profitability.

Net Margin

-1346.1%

5Y CAGR+2348.5pp

Syndax Pharmaceuticals Inc's net profit margin was -1346.1% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

N/A

R&D Spending

$241.6M

YoY+48.2%

5Y CAGR+41.2%

10Y CAGR+37.3%

Syndax Pharmaceuticals Inc invested $241.6M in research and development in fiscal year 2024. This represents an increase of 48.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SNDX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$23.7M	$0	$0-100.0%	$139.7M+9109.6%	$1.5M0.0%	$1.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$241.6M+48.2%	$163.0M+37.6%	$118.5M+34.3%	$88.2M+75.0%	$50.4M+17.3%	$43.0M
SG&A Expenses	$120.9M+80.6%	$66.9M+101.2%	$33.3M+31.8%	$25.2M+12.2%	$22.5M+40.1%	$16.1M
Operating Income	-$339.7M-47.7%	-$230.0M-51.5%	-$151.8M-678.8%	$26.2M+136.7%	-$71.4M-24.1%	-$57.5M
Interest Expense	$4.9M+2269.7%	$208K-93.4%	$3.1M+65.2%	$1.9M-19.4%	$2.4M	N/A
Income Tax	N/A	N/A	N/A	$0	$0	$0
Net Income	-$318.8M-52.3%	-$209.4M-40.2%	-$149.3M-699.1%	$24.9M+134.1%	-$73.2M-30.5%	-$56.0M
EPS (Diluted)	$-3.72-24.8%	$-2.98-21.1%	$-2.46-634.8%	$0.46+124.6%	$-1.87-1.6%	$-1.84

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$45.9M+20.8%	$38.0M+89.4%	$20.0M+161.0%	$7.7M+119.4%	$3.5M	$0	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$56.3M-9.6%	$62.2M+1.0%	$61.6M-5.9%	$65.5M+34.7%	$48.7M-13.9%	$56.5M	N/A	$39.1M
SG&A Expenses	$44.9M+2.5%	$43.8M+6.8%	$41.0M+8.9%	$37.7M+29.7%	$29.1M+26.2%	$23.0M	N/A	$17.3M
Operating Income	-$57.4M+17.2%	-$69.4M+17.2%	-$83.8M+13.1%	-$96.4M-29.8%	-$74.2M+6.7%	-$79.5M	N/A	-$56.4M
Interest Expense	$0-100.0%	$4K+100.0%	$2K-100.0%	$4.8M+10580.0%	$45K-18.2%	$55K	N/A	$70K
Income Tax	N/A	N/A	$0	N/A	N/A	$0	N/A	N/A
Net Income	-$60.7M+15.5%	-$71.8M+15.3%	-$84.8M+9.9%	-$94.2M-38.4%	-$68.1M+6.0%	-$72.4M	N/A	-$51.1M
EPS (Diluted)	$-0.70+15.7%	$-0.83+15.3%	$-0.98+10.1%	$-1.09-36.3%	$-0.80+5.9%	$-0.85	N/A	$-0.73

SNDX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$724.8M+18.3%	$612.9M+23.3%	$497.2M+10.6%	$449.7M+49.6%	$300.6M+373.2%	$63.5M
Current Assets	$603.1M+3.8%	$580.9M+18.6%	$489.8M+9.2%	$448.4M+50.0%	$298.9M+379.5%	$62.3M
Cash & Equivalents	$154.1M-47.8%	$295.4M+297.3%	$74.4M-66.5%	$222.0M+92.6%	$115.2M+368.3%	$24.6M
Inventory	$366K	$0	N/A	N/A	N/A	N/A
Accounts Receivable	$7.6M	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$436.7M+644.1%	$58.7M+97.0%	$29.8M-27.9%	$41.3M-14.7%	$48.4M+51.7%	$31.9M
Current Liabilities	$103.5M+78.2%	$58.1M+99.9%	$29.1M+40.5%	$20.7M+9.6%	$18.9M+2.7%	$18.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$288.1M-48.0%	$554.2M+18.6%	$467.4M+14.5%	$408.4M+61.9%	$252.2M+698.1%	$31.6M
Retained Earnings	-$1.2B-35.3%	-$902.4M-30.2%	-$693.0M-27.5%	-$543.7M+4.4%	-$568.6M-14.8%	-$495.5M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$551.8M-7.4%	$596.1M-7.0%	$640.7M-11.6%	$724.8M+52.0%	$476.9M-12.2%	$543.0M-11.4%	$612.9M+53.5%	$399.2M
Current Assets	$529.8M-0.3%	$531.7M-3.1%	$548.8M-9.0%	$603.1M+35.2%	$446.1M-1.7%	$453.9M-21.9%	$580.9M+52.5%	$381.0M
Cash & Equivalents	$116.8M+7.5%	$108.6M-29.5%	$154.0M-0.1%	$154.1M+46.2%	$105.4M-8.0%	$114.6M-61.2%	$295.4M+212.4%	$94.5M
Inventory	$25.0M+41.3%	$17.7M+279.4%	$4.7M+1174.3%	$366K	N/A	N/A	$0	N/A
Accounts Receivable	N/A	N/A	N/A	$7.6M	N/A	N/A	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$436.4M-0.5%	$438.7M+3.1%	$425.6M-2.5%	$436.7M+924.9%	$42.6M-16.7%	$51.1M-12.9%	$58.7M+46.6%	$40.0M
Current Liabilities	$114.2M+1.1%	$113.0M+19.5%	$94.6M-8.7%	$103.5M+143.8%	$42.5M-16.4%	$50.8M-12.5%	$58.1M+48.3%	$39.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$115.4M-26.7%	$157.4M-26.8%	$215.1M-25.4%	$288.1M-33.7%	$434.3M-11.7%	$491.9M-11.2%	$554.2M+54.3%	$359.2M
Retained Earnings	-$1.4B-4.4%	-$1.4B-5.5%	-$1.3B-6.9%	-$1.2B-17.1%	-$1.0B-7.0%	-$974.8M-8.0%	-$902.4M-8.7%	-$829.9M

SNDX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$274.9M-71.2%	-$160.6M-20.1%	-$133.7M-558.9%	$29.1M+140.9%	-$71.3M-40.8%	-$50.6M
Capital Expenditures	N/A	$0	$0-100.0%	$129K	$0	N/A
Free Cash Flow	N/A	-$160.6M-20.1%	-$133.7M-560.9%	$29.0M+140.7%	-$71.3M	N/A
Investing Cash Flow	-$219.8M-286.9%	$117.6M+163.2%	-$186.2M-355.5%	-$40.9M+71.3%	-$142.5M-1215.2%	$12.8M
Financing Cash Flow	$353.4M+33.8%	$264.1M+53.3%	$172.3M+45.4%	$118.5M-61.1%	$304.4M+965.5%	$28.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$70.5M+19.7%	-$87.8M+7.7%	-$95.2M-65.8%	-$57.4M+19.9%	-$71.6M+14.2%	-$83.5M-102.1%	-$41.3M+7.4%	-$44.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$72.4M+72.9%	$41.9M-55.5%	$94.1M+135.0%	-$269.0M-535.6%	$61.8M+162.1%	-$99.4M-510.2%	-$16.3M-140.6%	$40.1M
Financing Cash Flow	$6.3M+1039.4%	$551K-40.8%	$930K-99.7%	$347.4M+51294.2%	$676K-68.8%	$2.2M-99.2%	$258.5M+13864.5%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SNDX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1434.4%	N/A	N/A	18.8%+4726.9pp	-4708.2%-915.2pp	-3792.9%
Net Margin	-1346.1%	N/A	N/A	17.8%+4840.4pp	-4822.5%-1127.9pp	-3694.6%
Return on Equity	N/A	N/A	N/A	6.1%	N/A	N/A
Return on Assets	-44.0%-9.8pp	-34.2%-4.1pp	-30.0%-35.6pp	5.5%+29.9pp	-24.3%+63.9pp	-88.2%
Current Ratio	5.82-4.2	10.00-6.9	16.85-4.8	21.68+5.8	15.84+12.4	3.39
Debt-to-Equity	1.52+1.4	0.11+0.0	0.06-0.0	0.10-0.1	0.19-0.8	1.01
FCF Margin	N/A	N/A	N/A	20.8%+4718.2pp	-4697.4%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-125.2%+57.5pp	-182.7%+235.2pp	-417.9%+836.8pp	-1254.8%+865.7pp	-2120.5%	N/A	N/A	N/A
Net Margin	-132.4%+56.9pp	-189.3%+234.1pp	-423.3%+802.8pp	-1226.2%+718.5pp	-1944.7%	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-11.0%+1.0pp	-12.0%+1.2pp	-13.2%-0.3pp	-13.0%+1.3pp	-14.3%-0.9pp	-13.3%	N/A	-12.8%
Current Ratio	4.64-0.1	4.71-1.1	5.80-0.0	5.82-4.7	10.50+1.6	8.93-1.1	10.00+0.3	9.73
Debt-to-Equity	3.78+1.0	2.79+0.8	1.98+0.5	1.52+1.4	0.100.0	0.100.0	0.110.0	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Ardelyx ARDX

$1.7B

Vera Therapeutics, Inc. VERA

$3.0B

Biohaven BHVN

$1.5B

Tourmaline Bio TRML

$1.2B

Viridian Therapeutics Inc VRDN

$2.7B

Frequently Asked Questions

What is Syndax Pharmaceuticals Inc's annual revenue?

Syndax Pharmaceuticals Inc (SNDX) reported $23.7M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Syndax Pharmaceuticals Inc profitable?

No, Syndax Pharmaceuticals Inc (SNDX) reported a net income of -$318.8M in fiscal year 2024, with a net profit margin of -1346.1%.

What is Syndax Pharmaceuticals Inc's earnings per share (EPS)?

Syndax Pharmaceuticals Inc (SNDX) reported diluted earnings per share of $-3.72 for fiscal year 2024. This represents a -24.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Syndax Pharmaceuticals Inc's EBITDA?

Syndax Pharmaceuticals Inc (SNDX) had EBITDA of -$331.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Syndax Pharmaceuticals Inc's operating margin?

Syndax Pharmaceuticals Inc (SNDX) had an operating margin of -1434.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Syndax Pharmaceuticals Inc's net profit margin?

Syndax Pharmaceuticals Inc (SNDX) had a net profit margin of -1346.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Syndax Pharmaceuticals Inc's operating cash flow?

Syndax Pharmaceuticals Inc (SNDX) generated -$274.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Syndax Pharmaceuticals Inc's total assets?

Syndax Pharmaceuticals Inc (SNDX) had $724.8M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Syndax Pharmaceuticals Inc spend on research and development?

Syndax Pharmaceuticals Inc (SNDX) invested $241.6M in research and development during fiscal year 2024.

How many shares does Syndax Pharmaceuticals Inc have outstanding?

Syndax Pharmaceuticals Inc (SNDX) had 86M shares outstanding as of fiscal year 2024.

What is Syndax Pharmaceuticals Inc's current ratio?

Syndax Pharmaceuticals Inc (SNDX) had a current ratio of 5.82 as of fiscal year 2024, which is generally considered healthy.

What is Syndax Pharmaceuticals Inc's debt-to-equity ratio?

Syndax Pharmaceuticals Inc (SNDX) had a debt-to-equity ratio of 1.52 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Syndax Pharmaceuticals Inc's return on assets (ROA)?

Syndax Pharmaceuticals Inc (SNDX) had a return on assets of -44.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Syndax Pharmaceuticals Inc's cash runway?

Based on fiscal year 2024 data, Syndax Pharmaceuticals Inc (SNDX) had $154.1M in cash against an annual operating cash burn of $274.9M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Syndax Pharmaceuticals Inc's Piotroski F-Score?

Syndax Pharmaceuticals Inc (SNDX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Syndax Pharmaceuticals Inc's earnings high quality?

Syndax Pharmaceuticals Inc (SNDX) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Syndax Pharmaceuticals Inc cover its interest payments?

Syndax Pharmaceuticals Inc (SNDX) has an interest coverage ratio of -68.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.